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Introduction
Herpes simplex virus (HSV) is a ubiquitous DNA virus that can infect virtually
anywhere in the body, particularly when newborns are infected.1–3 However, in an
individual with a normal immune system, the most common sites of infection are the
mouth, genitalia, and eyes. In very young children, and in rare instances adults, the
brain may also become infected. HSV infections of the eye are the leading cause of
infectious corneal blindness in developed countries.4 Approximately 500,000 people
in the US are currently infected with ocular HSV.5,6 The costs of treatment for this
disease are in the tens of millions spent annually in the US alone.6 While most infections are unilateral, around 1.3%–12% of affected individuals have bilateral ocular
infections. Bilateral infections are seen mostly in immunocompromised patients.7–9
Infections can occur in both anterior and posterior segments of the eye, but it most
commonly infects the corneal epithelia.4,7,8 It is primarily diagnosed by its clinical
presentation, but atypical presentation of the infection can impede accurate diagnoses
and thus proper treatment.10
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Pathophysiology

HSV is a linear double-stranded DNA virus that is classified as an α-member of the
Herpesviridae family.5,11 Primary infection results after HSV spread via direct contact with mucous membrane of the host.5,11 In the case of ocular infections, the virus
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Abstract: Herpes simplex virus is responsible for numerous ocular diseases, the most common
of which is herpetic stromal keratitis. This is a recurrent infection of the cornea that typically
begins with a subclinical infection of the cornea that establishes a latent infection of sensory ganglia, most often the trigeminal ganglia. Recurring infections occur when the virus is reactivated
from latency and travels back to the cornea, where it restimulates an inflammatory response. This
inflammatory response can lead to decreased corneal sensation, scarring, and blindness. The
diagnosis of these lesions as the result of a recurrent herpes simplex virus infection can at times
be problematic. Currently, herpetic stromal keratitis is diagnosed by its clinical presentation
on the slit-lamp examination, but the literature does not always support the accuracy of these
clinical findings. Other diagnostic tests such as polymerase chain reaction assay, enzyme-linked
immunosorbent assay, immunofluorescent antibody, and viral cultures have provided more
definitive diagnosis, but also have some limitations. That said, accurate diagnosis is necessary
for proper treatment, in order to prevent serious consequences. Current treatment reduces the
severity of lesions and controls further viral spread, but does not provide a cure.
Keywords: herpes simplex virus, herpetic stromal keratitis, cornea
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Herpetic stromal keratitis (HSK) comprises three major
subtypes: epithelial, stromal, and endothelial (Figure 1).15
Clinical findings in epithelial keratitis include geographic
corneal ulcers with a dendritic tail or dendritic keratitis.
This occurs after direct invasion by the virus and is the most
common subtype.13,15 SK develops as a result of immune
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is transported following primary retrograde infection via
sensory neurons to establish latency in trigeminal ganglia;
here, it remains asymptomatic until reactivation of the virus
leads to secondary or recurrent infections.4,8,12,13 The host
cell’s DNA polymerase, located in the nucleus of the cell,
is required for HSV to transcribe and replicate.8,14

Figure 1 Representative images of various corneal damages due to HSV1 infection.
Notes: (A) Large herpetic epithelial dendrite at graft–host junction. (B) Large subepithelial bulla due to HSV endotheliitis. (C) Ring-lipid deposit surrounding a focal HSV
disciform keratitis. (D) Large geographic herpetic ulcer in HIV patient. (E) Herpetic keratouveitis with anterior chamber inflammation (layered hypopyon due to WBC
accumulation), small keratic precipitates (WBC aggregates on the corneal endothelial surface), and corneal edema (due to endothelial dysfunction). (F) Large herpetic
epithelial dendrite. (G) Postherpetic neurotrophic epithelial defect due to corneal nerve damage by HSV1. (H) Large herpetic corneal scar with iris incarceration to the side
of corneal perforation.
Abbreviations: HSV, herpes simplex virus; WBC, white blood cell.
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response to the virus. The stromal subtype can be further
divided into disciform keratitis, immune SK, and necrotizing
keratitis. Endothelial keratitis manifests as rejection line-like
keratic precipitates and stromal edema. Variation in presentation between different subtypes has posed a challenge in
accurately diagnosing this condition.15

Diagnosis
HSK is primarily diagnosed by its clinical presentation on
the slit-lamp examination.4 Common symptoms include
redness, discharge, watery eyes, irritation, itching, pain,
and photophobia. In most patients, symptoms begin to
subside after the first 2 weeks.4 The most common subtype,
epithelial keratitis, appears as coarse granular spots that
form punctuate lesions, but these quickly coalesce to form
dendritic lesions.16–18 A physical examination may reveal
whitened area.19 On the slit-lamp examination, epithelial
keratitis presents as a dendritic lesion with a terminal bulb,
swollen borders, and intraepithelial cell infiltration. 15 It
is visualized by staining the lesion with either lissamine
green or rose bengal dye.20 For atypical epithelial lesions,
polymerase chain reaction (PCR) has been used to confirm HSK.21 Newer methods, such as tear collection and
immunofluorescence antibody assay (IFA), have also been
employed to aid identification of epithelial lesions.22,23 SK
on physical examination appears opaque or whitened, due to
stromal infiltration.20,24 Similarly, the necrotizing form of SK
appears as gray-white or opaque, but there is accompanying
necrosis and ulceration on slit-lamp examination.20,24 Edema
and abscess may be apparent as well.4,25 In immunomediated
SK, necrosis or ulceration is lacking, but there is stromal
infiltration.26 Unfortunately, PCR has been less helpful for
identification of immunomediated SK. Another form of
HSK, disciform lesion, has a ground-glass appearance and is
disk shaped with stromal edema on slit-lamp examination.27
Lastly, the endothelial form, keratic precipitates, and iritis
may be visible. Stromal edema is also present.27 Enzymelinked immunosorbent assay (ELISA) and viral cultures have
been used as diagnostic tools for all subgroups of lesions.15,28
Dendritiform epithelial lesions on slit-lamp examination
are pathognomonic for keratitis. However, atypical lesions
can make diagnosis difficult.15 Factors affecting diagnosis
include duration of illness, systemic diseases, previous medication use, and corneal transplantation, as these can change
the appearances of lesions on slit-lamp examination.21
Misdiagnosis in clinical settings is not uncommon, as
other pathogens can present with similar lesions.10 Amebic
and fungal infections have been mistakenly identified as
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HSV keratitis.13 In a study conducted by Rübben et al, 8%
of the clinically diagnosed HSV lesions were identified
on PCR assay as lesions caused by another member of the
Herpesviridae family – varicella zoster virus.29 Similarly,
another study uncovered 5% of clinically diagnosed HSK
lesions as lesions caused by adenovirus, 3.2% as lesions
caused by cytomegalovirus, and 2.7% by enterovirus.30
When PCR was used to confirm clinical diagnosis of
epithelial dendritiform lesions, there was only moderate
correlation (K=0.485, P,0.0001) between diagnosis made
by an ophthalmologist and diagnosis made using PCR.10 In
a study designed to address the diagnosis of atypical HSK
lesions, Koizumi et al defined atypical lesions as those where
“dendritic or geographical ulcers with terminal bulbs and
epithelial infiltrations are not evident”. They found very
little agreement (P=0.22) between PCR results and clinical
diagnosis.21
While most diagnoses of HSK are based on clinical
presentation, PCR provides better sensitivity. In a study conducted by El-Aal et al, PCR detected 29.2% more cases than
cell culture.22 In another study, while viral culture identified
12% of suspected patients with HSK, PCR identified 88%
of suspected patients.22 PCR is highly sensitive, but large
variation has been observed in various studies between the
rate of HSV detection by PCR when compared to clinical
diagnosis.10 PCR is more likely to identify patients that
present with typical lesions or patients who have not used
antiviral medications (P=0.022). It is less responsive in
patients with atypical lesions or in patients who previously
used or currently use antiviral medications (P=0.968).28 It
has been hypothesized by McGilligan et al that because
SK is a result of immune response to the virus, rather than
the viral infection itself, it may explain the negative PCR
results. Variation was also seen (4%–6% variability) when
the same samples were reanalyzed using different amplification regions of the gene.10 In another study, there was an
80% decrease of detectable virus in patients who had been
taking 400 mg of acyclovir twice daily.31 This can lead to
reduction in PCR sensitivity.13 PCR-based tests can also
result in false negatives.31,32
Similarly, ophthalmologists use oxybuprocaine, a local
anesthetic that is used in conjunction with fluorescein-based
dye to visualize possible HSV corneal lesions better, but can
decrease the effectiveness of PCR by interfering with the
PCR reaction, resulting in a decrease of more than 2 logs
(DNA copies/sample).33 Other dyes, such as rose bengal and
lissamine green, also inhibit the detection of HSV DNA by
PCR assay.34
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PCR assays require corneal scrapings. Unfortunately,
patients with recurrent infections may have decreased corneal thickness, thus restricting the ophthalmologist from
performing corneal scraping to obtain a specimen.23 Alternatively, viral load can be determined from patient tears.23
Satpathy et al compared viruses collected by this less invasive technique with that collected by corneal scraping using
immunofluorescence assay, PCR, and viral titering.23 The
results indicated that immunofluorescence assay detected
viral antigen in 12.53% of tear specimens and 22.87% of
corneal scrapings, PCR detected the virus in 13.97% of tear
specimens and 36.66% of corneal scrapings. Lastly, infectious virus was detected from 5.2% of tears and 11.11% of
corneal scrapings. While PCR of virus collected from tears
was more sensitive than both viral isolation and immunofluorescence from tears, it was significantly less sensitive than
corneal scrapings (P,0.0005).23 Once again, the timing of
testing tear film is a concern, as the virus rarely persists as
long as the corneal lesions do.23
Along with PCR, ELISA has also been used to detect virus
in tear collections. Shoji et al measured HSV DNA using
real-time PCR and measured HSV-specific secretory immunoglobulin A (IgA) antibody using ELISA in tears of clinically
suspected HSK patients.15 Overall, sensitivity of ELISA was
49.2% and specificity 82.6%. On the other hand, sensitivity and
specificity for real-time PCR were higher at 55.8% and 100%,
respectively, in tears collected. However, when divided into
subgroups, real-time PCR detected HSV DNA levels in the
disciform keratitis subgroup (median 3.1×102 copies/sample),
significantly less than it detected HSV DNA in the dendritic/geographic keratitis subgroup (median 2.3×104 copies/
sample) (P,0.05, Mann–Whitney test). Detection of HSV
DNA was also low in the atypical subgroup.15 Furthermore,
viral load in tears decreased after day 11 of illness which could
have further increased false negatives in all subgroups.15
Viral culture is considered the gold standard for identifying
HSV.28 When compared to viral culture, clinical diagnosis
is only 55%–65% accurate.28 Unfortunately, culturing HSV
is time-consuming and can take a week or longer when few
infectious viruses are in the sample, and typically underestimates the number of patients whose disease is due to HSV.23,35
IFA has also been used to diagnose HSV and detects 33.3%
more positive cases than viral culture. It also had sensitivity of
80%, specificity of 71.4%, positive predictive value of 63.6%,
and negative predictive value of 81.8%. In other studies, the
sensitivity of IFA in diagnosing HSV ranged from 77% to
86%.22 However, sample size and false-positive and falsenegative results can unfavorably influence IFA.23

188

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

HSK is a leading cause of corneal blindness.4 Accurate
and prompt diagnosis is necessary to start the proper treatment and prevent further complications. Variation in different subtypes has posed a challenge to accurately diagnose
HSK.15 This has also prevented a unified or specific test from
properly diagnosing all of the different subtypes in a quick
and effective manner.

Challenges to clinical management
Most infections of HSK are self-limiting, even without
treatment. However, healing is prolonged without the use of
proper medication, and inappropriate treatment can worsen
corneal inflammation and lead to recurring lesions and vision
loss. On the other hand, other subtypes, such as geographic
epithelial keratitis, are difficult to treat and require prolonged
therapy.13 Although episodes can be self-limiting, it is essential to treat the infection at the earliest onset to reduce viral
replication, shorten disease course, and maintain latency, in
order to prevent further complications.
Current treatment for HSK includes acyclovir, ganciclovir, triflurothymidine, penciclovir, and valacyclovir.13,36
Acyclovir and its derivatives are nucleoside analogs that are
selectively phosphorylated by the virally encoded thymidine
kinase to be used as a substrate by DNA polymerase; this
drug is not a substrate for the host thymidine kinase, and
thus has a reduced side-effect profile. Once the analog is
phosphorylated, it is incorporated into the viral DNA as it
is being synthesized. Since this analog does not possess the
chemical structure for subsequent nucleosides to be added,
this results in chain termination and prevents viral replication
by inhibiting DNA elongation.8,37,38 Because it affects only
newly synthesized viral DNA, it does not cure infected cells
of the virus, but it does prevent new viruses from being produced. Since acyclovir has poor bioavailability, high doses
and increased frequency of administration are required.8,36,39,40
Valacyclovir, another nucleoside analog, has improved
bioavailability, and thus it has reduced frequency of administration and can lead to better patient adherence.41 Both
acyclovir and valacyclovir can cause nausea, vomiting,
diarrhea, and other gastrointestinal side effects.41 Ganciclovir
works in a similar manner as acyclovir. Though it has fewer
side effects, it can cause blurred vision, punctuate keratitis,
and eye irritation.8,42,43 Nonetheless, long-term treatment
with these nucleoside analogs has resulted in resistance,
especially in immunocompromised hosts, due to mutations
in thymidine kinase or in DNA polymerase, which are
selected for when the immune system does not efficiently
remove newly made infectious virus.5,8,36,44–46 Second-line
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treatment includes foscarnet and cidofovir, but they have
less specificity for viral DNA and are more likely to have
significant toxicity in patients. Early generation drugs, such
as idoxuridine, iododeoxyuridine, vidarabine, and trifluridine,
are no longer used, because of increased side-effect profile
and low bioavailability.8,47
As alluded to earlier, current treatment for HSV does not
provide a cure, but rather decreases duration of symptoms and
helps maintain the virus in latency. Recurrence can still occur,
despite treatment with antiviral drugs. In the HEDS study,
oral administration of 400 mg of acyclovir decreased ocular
HSV1 diseases by 45% (32% placebo vs 19% acyclovir).48 In
another study, recurrence of ocular HSV diseases was 23.1%
in patients taking acyclovir.49 Risk of recurrence is 20% by
2 years, 40% by 5 years, and 67% by 7 years, and the risk
increases with subsequent episodes. It should be stressed
that acyclovir does not prevent SK, as the pathogenesis of
SK is immunomediated, though by reducing viral load it
can reduce the magnitude of the inflammatory response.
Topical steroids help reduce progression of stromal inflammation, but they do not decrease epithelial disease.7 A quick
summary of current treatment for different subtypes can be
found in Table 1.
Relapsing and recurring stromal and endothelial diseases
significantly increase the risk of corneal scarring from fibrosis
and neovascularisation.4,7,8,11 Reactivation can be attributed
to stress, trauma, and ultraviolet radiation.51,52 Endothelial
keratitis due to recurrent infections can cause cell loss, permanent swelling, corneal scarring, opacities, tissue damage,
and irregular astigmatism.53,54 As the number of episodes
increases, corneal sensitivity to mechanical stimulation
decreases.53
Stromal infections are immunomediated and are the
leading cause of corneal blindness in developed countries.
They occur as a result of chronic viral reactivation, and
lead to neurotrophic keratitis, a degenerative condition.
A normal cornea is densely innervated, but lacks blood vessels. Subsequent episodes not only damage nerves, leading to
decreased corneal sensation (corneal hypoesthesia), but also
lead to angiogenesis, and neovascularization.53,54 Decreased
Table 1 Summary of current treatment for different subtypes
Subgroup

Treatment

Epithelial subtype
Stromal subtype

Antiviral agents13
Combination of topical corticosteroids
and antiviral agents27
Combination of topical corticosteroids
and antiviral agents50

Endothelial subtype

Clinical Ophthalmology 2017:11

corneal sensation leads to loss of the corneal blink reflex.54
This immunomediated reaction occurs as a result of cytokines released by CD4+ T cells.55–57 While recurrent episodes
of HSK can lead to stromal opacification, long-term use of
antiviral drugs to prevent future episodes can increase the
risk of resistance and toxicity.5,6,11 Since stromal response is
immunomediated, steroids can help decrease recurrence, but
they do not eliminate the virus.8,58
Additional changes due to HSK include changes in corneal
thickness. In a study conducted by Wilhelmus et al, corneal
thickness of disciform SK decreased 15% (95% confidence
interval 10%–20%).59 Other complications include necrotizing SK, where ulceration and necrosis of the cornea are
visible on slit-lamp examination.56,60 Keratitis has also been
shown to cause dryness in patients with stromal infection.53
Each subsequent episode increases the patient’s risk of
developing corneal scaring and blindness. As current treatment helps maintain latency and only shortens the course of
the disease, all infected patients are at risk of reactivation.
Corneal scarring that leads to blindness is an indication
for corneal transplantation. However, transplantation is
complicated by increased risk of graft rejection in patients
with HSK.10

Conclusion
HSK is an infection of the cornea caused by HSV. Primary
infection is the result of direct exposure of the host’s mucous
membranes to infectious HSV. Following primary infection
and the establishment of latency in the sensory ganglia, the
virus can be stimulated to enter an infectious cycle, from
which it returns to the cornea. Once there, this recurrent
infection can cause various complications, in particular an
inflammatory response, which if strong enough can compromise the integrity of the cornea, leading to corneal scarring
and in severe cases blindness.
HSK is primarily a clinical diagnosis based on the findings of the split-lamp examination. Dendritiform epithelial
lesions on slit-lamp examination are pathognomonic for
keratitis. However, previous studies have shown that ocular
lesions caused by cytomegalovirus, herpes zoster, adenovirus, and fungal infections have been misdiagnosed as HSK
lesions.7,10,11 Other diagnostic tests, such as PCR assay,
ELISA, IFA, and viral cultures, have provided a more definitive diagnosis, but have their own limitations. Additionally,
variation in different subtypes of keratitis has made diagnosis
of atypical lesions more difficult.
Accurate and prompt diagnosis is necessary to aid
the physician to know which treatment will have the best
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outcomes and thus prevent further complications. Latency
of HSV has prevented pharmacotherapy from eliminating
the virus. Current pharmacotherapy treatments have helped
decrease recurrence and maintain latency, but secondary
infections can still occur.23,24 Recurring lesions increase
a patient’s risk of developing fibrosis, scarring, and neovascularization of the cornea. SK, an immunomodulated
response, is the major cause of decreased corneal sensation
and blindness. Acyclovir is not effective against the inflammatory stage of SK, as there is little virus to be found during
peak inflammation. It should be noted that each episode of
recurrent infection increases the risk of subsequent episodes
and further complicates clinical management.4
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